Stockreport

Pharvaris Outlines 2026 Strategic Priorities

Pharvaris N.V. - Ordinary Shares  (PHVS) 
PDF Topline data from CHAPTER-3, a pivotal study of deucrictibant for prophylactic treatment of HAE attacks, anticipated in 3Q2026Preparation of NDA dossier of deucrictibant [Read more]